Search clinical trials for: [F-18] Fluorodopa Positron Emission Tomography

Total 876 results

Andrew Newberg

Not yet recruiting

Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA (FDOPAOM)

Parkinson Disease | Idiopathic Parkinson Disease

United States
University of Texas Southwestern Medical Center

Withdrawn

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

Breast Cancer

United States
Asan Medical Center

Completed

Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients (FPCIT)

Parkinson's Disease

Korea, Republic of
University of Texas Southwestern Medical Center

Completed

Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
University of California, San Francisco

Completed

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Plasma Cell Myeloma | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
University of Washington

Active, not recruiting

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Primary or Recurrent Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

Malignant Neoplasm

United States
Northwestern University

Completed

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia (PPA)

Dementia | Alzheimer Disease | Primary Progressive Aphasia

United States
Mayo Clinic

Completed

The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma

Glioma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer

Prostate Carcinoma

United States
Mayo Clinic
Yale University; Columbia University; National Institute on Aging (NIA); Brigham... and other collaborators

Completed

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS) (KEEPS)

Alzheimer Dementia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

Malignant Solid Neoplasm | Malignant Breast Neoplasm | Malignant Pancreatic Neoplasm | Malignant Colorectal Neoplasm

United States
AHS Cancer Control Alberta
Cross Cancer Institute

Terminated

An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs

Pancreatic Cancer

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Trevarx Biomedical, Inc

Recruiting

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Breast Carcinoma

United States
University of Utah

Terminated

Multi-Tracer Positron Emission Tomography in Patients With Solid Tumors

Malignant Neoplasm

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditions

United States
University of Virginia

Recruiting

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

Glioblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
University of Washington
National Cancer Institute (NCI)

Terminated

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Recurrent Breast Carcinoma | Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
Northwell Health

Completed

Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

Neuroendocrine Tumors

United States
University of Washington
National Cancer Institute (NCI)

Completed

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

Metastatic Malignant Neoplasm in the Brain | Recurrent Brain Neoplasm | Primary Brain Neoplasm

United States
Erik Mittra
National Cancer Institute (NCI)

Terminated

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

Untreated Childhood Brain Stem Glioma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Hormone Receptor Positive Breast Carcinoma | Metastatic Breast Carcinoma

United States, Puerto Rico, Ireland
Jonsson Comprehensive Cancer Center

Withdrawn

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

Glioma | Glioblastoma

United States
Jonsson Comprehensive Cancer Center
American Cancer Society, Inc.; LUNGevity Foundation

Recruiting

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Lung Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Metastatic Malignant Neoplasm in Lymph Node

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer

Metastatic Head and Neck Squamous Cell Carcinoma | Metastatic Malignant Neoplasm in the Spine

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Glioblastoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

Soft Tissue Sarcoma | Recurrent Soft Tissue Sarcoma | Resectable Soft Tissue Sarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Ependymoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Myxopapillary Ependymoma | Adult Oligodendroglioma | Adult Pilocytic... and other conditions

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

Lung Cancer

United States
Andrei Iagaru
Boston University; Canary Foundation

Recruiting

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

Current Smoker | Former Smoker | Multiple Pulmonary Nodules | Pulmonary Nodule | Cigarette Smoker

United States
Thomas Hope

Active, not recruiting

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms (UC-GlioFET)

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Low Grade Glioma | Intracranial Neoplasm | Recurrent World Health Organization (WHO) Grade II Glioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer

Breast Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

RefleXion PET/CT Imaging Performance in Patients With Various Malignancies

Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Estrogen Receptor-Positive Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Solid Neoplasm

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial

Kidney Cancer | Melanoma (Skin)

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Familial Adenomatous Polyposis | Deep Fibromatosis/Desmoid Tumor

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

Metastatic Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma in Cervical Lymph Node

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery

Glioblastoma

United States
Institute of Cancer Research, United Kingdom

Completed

Positron Emission Tomography in Detecting Testicle Cancer

Testicular Germ Cell Tumor

United Kingdom
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

Esophageal Cancer | Lung Cancer

United States
M.D. Anderson Cancer Center

Completed

Positron Emission Tomography for the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis

Myocarditis Acute

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States

Search clinical trials for: [F-18] Fluorodopa Positron Emission Tomography

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations